Combined Therapy Rationale: When and Why to Add IPL

If TFOS DEWS III has one practical lesson, it is that dry eye is rarely a single-driver disease (TFOS DEWS III, 2025, American Journal of Ophthalmology). When the drivers are plural, the most effective management is often plural too. That is the rationale for pairing OPE™ IPL with LM™ LLLT (PBM), both on eye-light®.

Complementary, not redundant

The two modalities do different jobs. LLLT acts broadly through a cellular mechanism, reaching the aqueous layer and the ocular surface and serving as the primary modality. IPL concentrates on the inflammatory and vascular drivers at the lid margin, warming and supporting the meibomian glands. Treat the lid with one and the broader surface with the other, and you address more of the patient's driver profile in a single plan.

Which patient benefits

The candidate for added IPL is typically one with significant meibomian gland dysfunction, visible lid-margin inflammation or telangiectasia, features of ocular rosacea, and an inadequate response to LLLT or lid measures alone. For milder, predominantly aqueous or surface-driven disease, LLLT alone is often sufficient. IPL is an adjunct for the lid-driven, inflammatory, more stubborn cases.

What the evidence supports

The combination has been tested head-to-head, which is the only legitimate basis for a comparative claim. Combined therapy outperformed an IPL-only comparator at eighteen months (Leite et al., 2025) and bettered competitor IPL-only devices on lipid layer thickness and symptoms (Castro et al., 2023). Read alongside the finding that LLLT alone outperformed IPL alone at two weeks (Giannaccare et al., 2022, Cornea), the picture is coherent: LLLT leads, IPL adds value selectively. See the evidence for combined therapy.

Safety shapes the decision

Safety is where the modalities diverge and where candidate selection bites. LLLT has a favourable profile with no absolute contraindications identified; IPL is more conditional, with photosensitivity history and photosensitising medications mattering. Where there is any concern, LLLT alone is the lower-risk pathway. Decisions follow the device IFU and clinical judgement. See patient selection and safety and tolerability.

Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.